Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance

At present, treatment options for osimertinib resistance are very limited. Dual inhibition of the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) significantly improved the progression-free survival (PFS) of advanced EGFR-mutant non–small cell lung cancer (NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Qingli, Hu, Yanhui, Cui, Qingan, Wu, Daoyuan, Mao, Yuefeng, Ma, Dongyang, Liu, Huaimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762231/
https://www.ncbi.nlm.nih.gov/pubmed/35046801
http://dx.doi.org/10.3389/fphar.2021.746707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762231/
https://www.ncbi.nlm.nih.gov/pubmed/35046801
http://dx.doi.org/10.3389/fphar.2021.746707

Ejemplares similares